Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug-induced cholestasis.

Lakshumanan S Velayudham1, Geoffrey C Farrell

  • 1Storr Liver Unit, Westmead Millennium Institute, University of Sydney, NSW, Australia.

Expert Opinion on Drug Safety
|August 9, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hepatitis C Virus Antiviral Drug Resistance and Salvage Therapy Outcomes Across Australia.

Open forum infectious diseases·2024
Same author

Role of Cholesterol-Associated Steatohepatitis in the Development of NASH.

Hepatology communications·2021
Same author

Non-alcoholic fatty liver disease: Not time for an obituary just yet!

Journal of hepatology·2020
Same author

Exercise retards hepatocarcinogenesis in obese mice independently of weight control.

Journal of hepatology·2020
Same author

Cholesterol Crystals in Hepatocyte Lipid Droplets Are Strongly Associated With Human Nonalcoholic Steatohepatitis.

Hepatology communications·2019
Same author

Non-alcoholic fatty liver disease.

Internal medicine journal·2019
Same journal

Could anticholinergics accelerate ALS progression? A critical perspective on drug safety and disease vulnerability.

Expert opinion on drug safety·2026
Same journal

Safety profile of teprotumumab-trbw, the first and only FDA-approved treatment for thyroid-associated ophthalmopathy.

Expert opinion on drug safety·2026
Same journal

A systematic review and meta-analysis of safety and efficacy parameters of sotatercept in the therapy of pulmonary arterial hypertension.

Expert opinion on drug safety·2026
Same journal

Tirzepatide data: safety first is safety always!

Expert opinion on drug safety·2026
Same journal

An update on the safety of biologics for the treatment of psoriasis.

Expert opinion on drug safety·2026
Same journal

Recent advances in trastuzumab and its antibody-drug conjugates-related liver injury.

Expert opinion on drug safety·2026
See all related articles

Drug-induced cholestasis, a severe liver condition impairing bile flow, affects 17% of hepatic adverse drug reactions. Early detection and prompt withdrawal are key for prevention and management.

Area of Science:

  • Hepatology
  • Pharmacology
  • Gastroenterology

Background:

  • Drug-induced cholestasis is a significant cause of liver injury, accounting for approximately 17% of hepatic adverse drug reactions.
  • It presents as 'pure' cholestasis or 'cholestatic hepatitis', involving impaired bile flow and liver inflammation.

Purpose of the Study:

  • To review the diagnosis, pathogenesis, prevention, and management of drug-induced cholestasis.
  • To highlight frequently and newly described causes of drug-induced cholestasis.

Main Methods:

  • Literature review of drug-induced cholestasis.
  • Analysis of causes, clinical presentations, and management strategies.

Main Results:

  • Common causes include estrogens, anabolic steroids, antimicrobials, NSAIDs, and specific antibiotics like amoxicillin-clavulanate.

Related Experiment Videos

  • Chronic cholestasis can lead to vanishing bile duct syndrome or secondary sclerosing cholangitis.
  • Ursodeoxycholic acid (UDCA) shows promise in arresting progressive cholestasis.

    • Conclusions:

    • Early detection of liver injury and prompt drug withdrawal are crucial for preventing severe outcomes.
    • While genetic predisposition is suggested, no reliable pretreatment tests exist.
    • Management focuses on symptomatic relief and vitamin correction, with UDCA as a potential therapeutic agent.